Managing Wegovy Constipation Across All Treatment Doses

Understanding Wegovy Constipation Across All Treatment Phases

Wegovy constipation typically emerges during the initial weeks of treatment as your digestive system adapts to semaglutide's effects on gastric emptying and gut motility. Clinical data from the STEP trials indicates that gastrointestinal side effects, including constipation, are most pronounced during dose escalation phases—specifically when transitioning from 0.25mg to 0.5mg and again when reaching the 1mg dose. The advantage of accessing all five Wegovy doses from a single pharmacy means your clinical team can provide consistent, personalised guidance for managing constipation at each specific dose level.

At EverydayMeds, we've observed that patients who maintain continuity with one pharmacy throughout their entire dose escalation journey report better management of side effects like constipation. Our clinical monitoring system tracks your progress from the initial 0.25mg starter dose through to the 2.4mg maintenance phase, allowing our prescribers to provide targeted advice for constipation relief that's appropriate for each specific dose strength and treatment week.

Complete Wegovy Dose Range: Pricing and Availability

EverydayMeds maintains comprehensive stock of all Wegovy doses with transparent pricing: 0.25mg starter pens at £79.99, 0.5mg at £94.99, 1mg at £99.99, 1.7mg at £139.99, and the 2.4mg maintenance dose at £209.99. New customers can apply code FIRST40 at checkout, while returning customers benefit from code DOSE25. Our Getting Started bundles, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, ensure you have consecutive doses ready without supply interruption during the critical early weeks when constipation is most likely to occur.

For patients concerned about managing Wegovy constipation long-term, our Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99, offering peace of mind that your treatment won't be disrupted by stock shortages. This complete dose availability means you can focus on managing side effects and achieving your weight management goals rather than worrying about sourcing your next prescription from different suppliers who may not understand your treatment history.

Clinical Evidence: Wegovy Constipation in STEP Trials

The landmark STEP trials, including Wilding et al., NEJM, 2021, documented constipation as occurring in approximately 24% of patients receiving Wegovy compared to 11% on placebo. Importantly, trial data showed that constipation was generally mild to moderate in severity and tended to decrease in frequency after the initial dose escalation period. Most patients who experienced Wegovy constipation found it manageable with appropriate dietary modifications and hydration strategies.

STEP trial investigators noted that gastrointestinal side effects, including constipation, were most common during the first 12-16 weeks of treatment—precisely the period covering dose escalation from 0.25mg through 1.7mg. The clinical evidence supports the importance of having consistent medical oversight during this critical phase, which is why EverydayMeds' complete dose availability ensures uninterrupted clinical monitoring throughout your entire treatment journey.

How Wegovy Works and Its Effects on Digestive Function

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural incretin hormones your body produces after eating. This mechanism works by slowing gastric emptying—the rate at which food moves from your stomach into your small intestine—which contributes to increased feelings of fullness and reduced appetite. However, this slower gastric emptying can also affect overall digestive transit time, potentially leading to constipation, particularly during the initial weeks as your system adjusts. The medication also influences gut motility through GLP-1 receptors in the gastrointestinal tract, which can temporarily alter normal bowel patterns. Understanding this mechanism helps explain why Wegovy constipation is most noticeable during dose escalation phases and typically improves as your body adapts to each new dose level.

Streamlined Ordering Process for All Wegovy Doses

Accessing any Wegovy dose through EverydayMeds begins with our 3-minute online clinical assessment, which includes specific questions about your gastrointestinal health and any history of constipation. Our prescribers review your assessment within 3 working days (or 24 hours with express service) and can provide personalised advice for managing potential side effects based on your chosen dose. Once approved, all Wegovy pens are dispatched via next-day cold-chain delivery, maintaining the 2-8°C temperature requirement throughout transit. This efficient process ensures minimal delays between dose escalations, helping maintain the precise timing that's crucial for minimising side effects like constipation. Our pharmacy team coordinates your entire treatment schedule, sending reminders when it's time to progress to your next dose and checking in about any side effects you may be experiencing.

Storage Requirements and Dose Escalation Timeline

All Wegovy doses must be stored in your refrigerator at 2-8°C before first use, though each pen can be kept at room temperature (below 30°C) for up to 6 weeks once removed from cold storage—a significant advantage over some alternatives. The mandatory dose escalation follows a specific timeline: 0.25mg for weeks 1-4, 0.5mg for weeks 5-8, 1mg for weeks 9-12, 1.7mg for weeks 13-16, and 2.4mg from week 17 onwards as your maintenance dose. Each dose increase gives your digestive system time to adapt, potentially reducing the severity of constipation as you progress. The FlexTouch pen design makes self-injection straightforward at every dose level, with clear dose markings to prevent confusion. Having all doses readily available from EverydayMeds eliminates the risk of treatment interruption, which could reset your tolerance and potentially worsen side effects like constipation when restarting.

Dose-Specific Constipation Management Throughout Treatment

Managing Wegovy constipation requires different strategies at different dose levels, which is why continuous care from a single pharmacy team proves invaluable. During the 0.25mg and 0.5mg starter phases, increasing water intake and dietary fibre often provides sufficient relief, while higher doses like 1.7mg and 2.4mg may require more structured bowel management strategies. Our clinical team provides dose-specific guidance, recognising that constipation patterns often change as you progress through treatment phases.

Patients accessing all their Wegovy doses through EverydayMeds benefit from consistent clinical records that track constipation patterns alongside dose progression. This continuity allows our prescribers to identify which dose transitions pose the greatest risk for each individual patient and provide proactive management strategies. The comprehensive approach prevents the fragmented care that can occur when patients source different doses from different suppliers, potentially missing crucial patterns in side effect management.

Secure Your Complete Wegovy Treatment Journey

Ready to begin or continue your Wegovy treatment with complete dose security and expert constipation management? Visit our Wegovy collection at https://everydaymeds.co.uk/collections/wegovy to access all doses from 0.25mg through 2.4mg with transparent pricing and immediate availability. New customers can use code FIRST40 at checkout, while returning customers apply code DOSE25 for preferred rates. Our GPhC-registered pharmacy (#9012878) ensures pharmaceutical-grade standards throughout your treatment, from initial assessment through long-term maintenance therapy. Don't let supply concerns or fragmented care compromise your weight management goals—secure your complete treatment pathway today. Start your clinical assessment now and join thousands of patients who trust EverydayMeds for their entire Wegovy journey, knowing that expert support and every dose they'll need is consistently available.

Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026